Perspective Therapeutics (CATX) 8-K Summary (Nov 3, 2025)
The Company filed an 8-K disclosing the execution of Amended and Restated Employment Agreements for key executives: CEO Spoor, CAO Hunt, and CMO Puhlmann.
Material Changes:
- Base Salaries Updated: Reflecting current compensation levels.
- Change in Control (CIC) Provisions Revised: The agreements now detail enhanced severance packages triggered if an Executive is terminated without Cause or resigns for Good Reason during a 15-month window surrounding a CIC.
CIC Severance Highlights:
- Cash Severance: